GlassScriptPhysician profile
Nusrat Ahsan
NPI 1558416537
$1,855.05
in general payments reported to CMS, 2019-2025
23 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $66.27 · 2021: $18.55 · 2022: $174 · 2023: $271 · 2024: $505 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $491.74 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $238.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $210.26 | 2019-2025 | Repatha, Otezla, Prolia |
| Merck Sharp & Dohme LLC | $99.26 | 2019-2025 | M-M-R II, Capvaxive, Gardasil 9 |
| Pfizer INC. | $97.63 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $94.72 | 2022-2023 | |
| Exact Sciences Corporation | $94.47 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $92.99 | 2025 | Mounjaro, Kisunla |
| Inari Medical, INC. | $67.85 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $55.73 | 2019-2022 | |
| Ucb, INC. | $43.61 | 2024 | Nayzilam |
| Edwards Lifesciences Corporation | $36.86 | 2021-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Averitas Pharma INC. | $28.18 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $26.00 | 2024 | Jynarque |
| Sanofi Pasteur INC. | $25.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.65 | 2025 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $20.47 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $20.20 | 2024 | Zoryve |
| Boston Scientific Corporation | $18.99 | 2025 | Wavewriter Alpha Prime 16 |
| Lucid Diagnostics INC. | $18.67 | 2023 | |
| Astellas Pharma US INC | $17.41 | 2019 | |
| Ibsa Pharma INC. | $16.16 | 2022 | |
| Allergan, INC. | $15.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nusrat Ahsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.